Arcus Biosciences Inc
$ 23.30
5.33%
11 Jun - close price
- Market Cap 2,973,277,000 USD
- Current Price $ 23.30
- High / Low $ 23.88 / 21.98
- Stock P/E N/A
- Book Value 4.17
- EPS -3.17
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.70 %
- 52 Week High 28.72
- 52 Week Low 7.91
About
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Analyst Target Price
$35.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-25 | 2025-10-28 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-21 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -1.02 | -0.89 | -1.27 | 0 | -1.14 | -1.03 | -1 | -1.02 | 0.19 | -1.08 | -0.94 | -1.04 |
| Estimated EPS | -0.83 | -1.1 | -1.33 | -1.17 | -1.08 | -1.2031 | -1.07 | -1.39 | -1.03 | -1 | -1.1 | -1.08 |
| Surprise | -0.19 | 0.21 | 0.06 | 1.17 | -0.06 | 0.1731 | 0.07 | 0.37 | 1.22 | -0.08 | 0.16 | 0.04 |
| Surprise Percentage | -22.8916% | 19.0909% | 4.5113% | 100% | -5.5556% | 14.3878% | 6.5421% | 26.6187% | 118.4466% | -8% | 14.5455% | 3.7037% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.81 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RCUS
2026-06-11 19:48:08
Arcus Biosciences, Inc. (RCUS) shares surged 6.9% to $23.64 on Thursday, driven by a broad rally across the biotechnology sector. The increase was attributed to coordinated buying among biotech peers, indicating renewed investor interest in growth-oriented healthcare equities rather than company-specific news. Investors are advised to monitor the sector's sustained momentum and potential company-specific catalysts for Arcus.
2026-06-11 17:41:08
Arcus Biosciences is collaborating with Bristol Myers Squibb on a clinical trial (ROSETTA RCC-208) involving Arcus's HIF-2a inhibitor, casdatifan, for renal cell carcinoma. This non-exclusive deal means any positive data from casdatifan's inclusion in new combination arms will benefit Arcus's economics, potentially influencing investor perspective on its upcoming 2026 RCC readouts and long-term revenue. While this collaboration broadens casdatifan's testing, the primary catalyst for Arcus remains the pivotal 'go or no go' decisions for RCC in 2026.
2026-06-10 16:10:22
Arcus Biosciences (RCUS) shares fell 7.0% despite LifeSci Capital initiating coverage with an "Outperform" rating and a $46 price target, significantly higher than its current trading price of $22.00. This disconnect highlights the volatile nature of biotech stocks, where clinical developments and regulatory news often outweigh analyst optimism. Investors may be de-risking positions or reacting to broader sector weakness, suggesting caution despite the potential long-term upside identified by the analyst.
2026-06-10 08:39:28
This article provides the transcript from the Arcus Biosciences Inc. (NYSE:RCUS) presentation at the Goldman Sachs Healthcare Conference. Terry Rosen, Chairman, CEO, and Co-Founder, introduced the company's focus on strong R&D, particularly in small molecules where existing validation exists but better molecules are needed. He highlighted "Casdatafan" as their most valuable program.
2026-06-10 08:39:28
Arcus Biosciences presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its lead oncology asset, casdatifan, for renal cell carcinoma, which it projects as a $5-10 billion commercial opportunity. The company emphasized its robust financial position, with cash reserves extending into late 2028, and a diverse pipeline beyond casdatifan, including immunology candidates. Despite a Q1 2026 net loss, analysts maintain a "Buy" consensus with a median price target of $34.50, reflecting confidence in its strategic partnerships and clinical development.
2026-06-09 20:09:56
Arcus Biosciences, a clinical-stage biopharmaceutical company, announced that its Compensation Committee granted a new employee inducement equity awards. These awards include options to purchase 2,850 shares of common stock at an exercise price of $23.32 and restricted stock units to acquire 1,450 shares. This grant was made under the company's 2020 Inducement Plan, in line with the "inducement exception" of NYSE Listed Company Manual Rule 303A.08.
